MOTS-c vs SS-31 (Elamipretide) | Research Comparison

MOTS-c and SS-31 (Elamipretide) are both mitochondria-targeting research compounds, but they act through fundamentally different mechanisms and address different aspects of mitochondrial biology. MOTS-c is a mitochondrial-derived peptide that regulates nuclear gene expression and AMPK signalling, while SS-31 is a membrane-targeted tetrapeptide that stabilises the inner mitochondrial membrane via cardiolipin binding. Understanding these differences is essential for selecting the appropriate tool compound for a given experimental question.

At a Glance

Mechanism of Action

MOTS-c

MOTS-c is encoded within the mitochondrial genome and translocates from the mitochondria to the nucleus in response to metabolic stress. In the nucleus, it regulates gene expression involved in metabolic adaptation. Its primary mechanism involves modulation of the folate cycle and one-carbon metabolism, leading to AICAR accumulation and downstream AMPK activation. AMPK then drives glucose uptake, fatty acid oxidation and mitochondrial biogenesis in laboratory models.

SS-31 (Elamipretide)

SS-31 selectively accumulates in the inner mitochondrial membrane where it binds to cardiolipin — a phospholipid essential for ETC supercomplex organisation. By stabilising cardiolipin-cytochrome c interactions, SS-31 preserves ETC complex activity, reduces electron leak and limits mitochondrial ROS generation. It acts directly at the membrane level without nuclear translocation, making it a structurally and mechanistically distinct tool from MOTS-c.

Key Research Differences

Metabolic vs Structural Intervention

MOTS-c is a metabolic signalling peptide — it reprograms cellular metabolism through AMPK and nuclear gene regulation. SS-31 is a structural stabiliser — it preserves mitochondrial membrane integrity and ETC function. These are complementary rather than overlapping mechanisms, and the choice depends on whether the experimental question concerns metabolic pathway regulation or mitochondrial membrane biophysics.

ROS Reduction Pathway

Both compounds reduce mitochondrial ROS in laboratory models, but through different routes. SS-31 directly limits electron leak at the ETC by stabilising cardiolipin-ETC interactions. MOTS-c reduces ROS indirectly through AMPK-mediated metabolic reprogramming and improved mitochondrial efficiency. For experiments specifically studying ETC-derived ROS, SS-31 is the more direct tool.

Ageing & Metabolic Research

MOTS-c is the preferred compound for research into metabolic ageing, exercise-related metabolic adaptation and insulin sensitivity, as its AMPK-activating properties are central to these pathways. SS-31 is preferred for research into mitochondrial dysfunction associated with ischaemia-reperfusion injury, age-related bioenergetic decline and cardiolipin-related membrane pathology.

Combined Use in Research

MOTS-c and SS-31 can be used together in laboratory models to study both metabolic signalling and mitochondrial membrane integrity simultaneously. Their non-overlapping mechanisms make them suitable for combination experimental designs investigating the full spectrum of mitochondrial health — from membrane structure to metabolic gene regulation.

Choosing Between Them for Research

For AMPK pathway research, metabolic regulation, insulin sensitivity or exercise mimetic studies, MOTS-c is the appropriate tool. For ETC stabilisation, cardiolipin biology, ROS reduction or ischaemia-reperfusion models, SS-31 is preferred. Both are available from Solatide Biosciences, independently third-party tested to ≥99% purity.

Related Resources